Literature DB >> 3028819

Evidence for an association between CD23 and the receptor for a low molecular weight B cell growth factor.

J Gordon, A J Webb, L Walker, G R Guy, M Rowe.   

Abstract

Low molecular weight B cell growth factor (BCGF) and a monoclonal antibody (MHM6) to the 45-kDa, B lineage-restricted, CD23 activation antigen (BLAST-2; EBVCS) were found to be indistinguishable in their biological effects. Individually, both augmented DNA synthesis in activated, but not resting, B lymphocytes while no additional enhancement resulted from using the two agonists in combination. Furthermore, by increasing the expression of Tac, both MHM6 and BCGF promoted activated B cells to respond more vigorously to the late addition of recombinant interleukin 2. The presence of BCGF during B cell activations was found to down-regulate the expression of the CD23 antigen while the coating of activated cells with MHM6 antibody diminished their capacity to absorb BCGF activity. The findings demonstrate that CD23 and a low molecular weight BCGF deliver a comparable growth-promoting signal to activated B cells. A possible relationship between CD23 and the receptor for the low molecular weight BCGF is discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3028819     DOI: 10.1002/eji.1830161225

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  20 in total

Review 1.  The receptor for the Fc region of IgE.

Authors:  A D Keegan; D H Conrad
Journal:  Springer Semin Immunopathol       Date:  1990

2.  Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity.

Authors:  D Wang; D Liebowitz; F Wang; C Gregory; A Rickinson; R Larson; T Springer; E Kieff
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

3.  Subset of natural killer cells is induced by immune complexes to display Fc receptors for IgE and IgA and demonstrates isotype regulatory function.

Authors:  H Kimata; A Saxon
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

Review 4.  B-cell stimulatory factors (BSFs): molecular structure, biological function, and regulation of expression.

Authors:  T Kishimoto
Journal:  J Clin Immunol       Date:  1987-09       Impact factor: 8.317

5.  Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23.

Authors:  F Wang; C D Gregory; M Rowe; A B Rickinson; D Wang; M Birkenbach; H Kikutani; T Kishimoto; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

6.  Binding site for IgE of the human lymphocyte low-affinity Fc epsilon receptor (Fc epsilon RII/CD23) is confined to the domain homologous with animal lectins.

Authors:  B Bettler; R Maier; D Rüegg; H Hofstetter
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

7.  Fyn tyrosine kinase associated with Fc epsilon RII/CD23: possible multiple roles in lymphocyte activation.

Authors:  K Sugie; T Kawakami; Y Maeda; T Kawabe; A Uchida; J Yodoi
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

8.  Cell-cell interactions for CD23 expression and soluble CD23 release from peripheral lymphocytes of atopic donors.

Authors:  K Kicza; A Fischer; T Pfeil; J Bujanowski-Weber; W König
Journal:  Immunology       Date:  1989-12       Impact factor: 7.397

9.  Detection and characterization of IgE-binding factors (IgE-BF) within supernatants of the cell line RPMI-8866, normal human sera and sera from atopic patients.

Authors:  J Bujanowski-Weber; I Knöller; B Brings; T Pfeil; W König
Journal:  Immunology       Date:  1988-09       Impact factor: 7.397

10.  The marmoset B-lymphoblastoid cell line (B95-8) produces and responds to B-cell growth and differentiation factors: role of shed CD23 (sCD23).

Authors:  R E Callard; Y L Lau; J G Shields; S H Smith; J Cairns; L Flores-Romo; J Gordon
Journal:  Immunology       Date:  1988-11       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.